Evoked potentails and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience
- 337 Downloads
Effectiveness of enzyme replacement therapy (ERT) in reverting hematologic, skeletal, and visceral symptoms in Gaucher disease (GD) has been demonstrated, although, its efficacy in neurologic involvement is still debated.
We evaluated the extent of neuro-cognitive dysfunction using brain stem evoked potential in GD3 patients, age-matched controls, and GD1 patients without neurological manifestations served as disease control group.
Study included 56 GD (36 had type 1, 20 had type 3) under ERT. Investigations included complete blood count, beta glucosidase assay in peipheral leucocytes, plasma chitotriosidase and bone marrow examination, electroencephalography, brain stem auditory (AEP), somatosensory (SSEP) and visual evoked potentials (VEP) as well as IQ testing.
Both types of GD showed significantly higher mean latency at 75 on left eye, lower PP amplitude ratio, higher latency at 75, 100, 145, lower amplitude, and higher Lat Diff LT-RT ms and Lt-Rt % compared to controls (p < 0.05) with no difference between both groups in other values of VEP. Both groups showed significantly prolonged latency of N 13–19 compared to controls (p < 0.05) with positive correlation between age and duration of therapy with parameters of SSEP (p < 0.01). Both groups of GD had significantly prolonged latency of the mean waves of AEP compared to controls (p < 0.05) with no significant difference between both groups. There was a negative correlation between age and waves II, III, I–III, I–V and threshold values of AEP. IQ level was positively correlated with AEP values. Severity scoring tool was positively correlated with AEP and SSEP values.
Electrophysiological abnormalities were present in both types of GD and have been correlated to cognitive function and disease characteristics.
KeywordsEnzyme Replacement Therapy Gauche Disease Visual Evoke Potential Miglustat Gauche Disease Type
Conflict of interest
- Barranger J, Rice E (1993) An overview of Gaucher disease. Gaucher Clin Perspect 1:1–5Google Scholar
- Beutler E, Grabowski G (2000) Gaucher disease. In: Scriver C, Sly W, Childs B et al (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3663–3668Google Scholar
- Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Valle D, Beudet A, Sly WS (eds) The metabolic and molecular bases of inherited diseases, vol III. McGraw-Hill, New York, pp 3635–3668Google Scholar
- Chiappa KH (1990) Evoked potentials in clinical medicine, 2nd edn. KH Chiappa, New YorkGoogle Scholar
- Khalifa A, Tantawy A, Monir E, Sadek A, Tiseer N (2010) Immune dysfunction in patients with Gaucher disease: impact of disease severity and enzyme replacement therapy. Haematologica 95(suppl2):37Google Scholar
- Leigh RJ, Zee D (1999) The neurology of eye movements, 3rd edn. Oxford University Press, OxfordGoogle Scholar
- Luckasson R, Coulter DL, Polloway EA, Reiss S, Schalock RL, Snell ME, Spitalnick DM, Stark JA (1992) Mental retardation: definition, classification, and systems of supports, 9th edn. American Association on Mental Retardation, Washington, DCGoogle Scholar
- Martins AM (1999) Inborn errors of metabolism: a clinical overview. Sao Paulo Med J 117251–265Google Scholar
- Martins AM, Valadares ER, Porta G, Coelho J, Semionato Filho J, Pianovski MA, Kerstenetzky MS, Montoril Mde F, Aranda PC, Pires RF, Mota RM, Bortolheiro TC, Brazilian Study Group on Gaucher Disease and other Lysosomal Storage Diseases (2009a) Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr 155(4 Suppl):S10–S18PubMedCrossRefGoogle Scholar
- Musiek F, Baran J (1991) Assessment of the human central auditory ner-vous system. In: Altschler R, Bobbin R, Cloppton B, Hoffman D (eds) Neurobiology of Hearing: The Central Auditory System. Raven, New York, pp 411–437Google Scholar
- Tylki-Szymańska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E (2010) Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis 33(4):339–346PubMedCrossRefGoogle Scholar
- World Health Organization (2006) WHO Child Growth Standards. WHO, GenevaGoogle Scholar